Defcort Tablet
Tablet
Eskayef Pharmaceuticals Ltd.Generic:
DeflazacortWeight:
24 mgbest Price:
৳ 30.00Generic
Deflazacort
Indications
Deflazacort is indicated in- Anaphylaxis, asthma, severe hypersensitivity reactions Rheumatoid arthritis, juvenile chronic arthritis, polymyalgia rheumatica Systemic lupus erythematosus, dermatomyositis, mixed connective tissue disease (other than systemic sclerosis), polyartritis nodosa, sarcoidosis ... Read moreDeflazacort is indicated in- Anaphylaxis, asthma, severe hypersensitivity reactions Rheumatoid arthritis, juvenile chronic arthritis, polymyalgia rheumatica Systemic lupus erythematosus, dermatomyositis, mixed connective tissue disease (other than systemic sclerosis), polyartritis nodosa, sarcoidosis Pemphigus,bullous pemphigoid, pyoderma gangrenosum Minimal change nephrotic syndrome, acute interstitial nephritis Rheumatic carditis Ulcerative colitis, Crohn's disease Uveitis, optic neuritis Autoimmune haemolytic anaemia, idiopathic thrombocytopenic purpura Acute and lymphatic leukaemia, malignant lymphoma, multiple myeloma Immune suppression in transplantation
Pharmacology
Deflazacort provides anti-inflammatory action by inhibiting Phospholipase A2 enzyme which is responsible for prostaglandin synthesis. Besides Deflazacort decreases the release of certain chemicals that are important in the immune system. By decreasing the release of these chemicals Deflazacort provides immunosuppressive action.
Contraindications
Hypersensitivity to or any of the ingredients. Patients receiving live virus immunization.
Side Effects
GI disturbances, musculoskeletal, endocrine, neuropsychiatric, ophthalmic, fluid and electrolyte disturbances; susceptible to infection, impaired healing, hypersensitivity, skin atrophy, striae, telangiectasia, acne, myocardial rupture following recent Ml, thromboembolism.
Pregnancy And Lactation
Pregnancy: Deflazacort does cross the placenta. However, when administered for prolonged periods or repeatedly during pregnancy, corticosteroids may increase the risk of intrauterine growth retardation. As with all drugs, corticosteroids should only be prescribed when the benefits to the mother and child outweigh the risks. Nursing Mother: Corticosteroids are excreted in breast milk, although no data are available for Deflazacort. Doses of up to 50 mg daily of Deflazacort are unlikely to cause systemic effects in the infant. Infants of mothers taking higher doses than this may have a degree of adrenal suppression but the benefits of breastfeeding are likely to outweigh any theoretical risk.
Therapeutic
Store in a cool (below 25°C) and dry place, protected from light & moisture. Keep out of the reach of children.
Over The Counter Products
